Abstract Library

#3012 Causes of Death Following Neuroendocrine Tumors Diagnosis: A United States Population-Based Analysis

Introduction: Neuroendocrine tumors (NET) are heterogeneous in terms of prognosis based on location, grade, and stage.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Saad A, Halfdanarson T, Starr J, Sonbol M,

Keywords: neuroendocrine tumors, survivorship, non-cancer causes of death,

#2686 Survivorship Care Model for Patients with Metastatic Neuroendocrine Tumors

Introduction: Neuroendocrine tumors(NET)are rare often indolent tumors. Approximately 22% of patients (pt's) present with metastatic disease at diagnosis and can live with metastatic disease for years. These pt's often don't identify as cancer survivors and don't meet the criteria for care in traditional survivorship clinics

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laffan A

Authors: Laffan A,

Keywords: neuroendocrine, survivorship, multidisciplinary, metastatic,

#662 Sequlae and Survivorship in Neuroendocrine Patients Treated with 131I-MIBG

Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Sze C, Grossman A, Amendra D, Shieh S, Plowman N,

Keywords: neuroendocrine tumors, chromaffin cell tumors, radionuclide therapy, survival, long-term sequelae ,